Society of Nuclear Medicine and Molecular Imaging (SNMMI)  leadership and a panel of experts announced today the most striking research being presented at the 2014 SNMMI Annual Meeting at the America’s Center convention center from June 7-11. This included the abstract of the year outlining how sentinel lymph node SPECT/CT imaging bests lymphoscintigraphy.

Acute myocardial infarction causes thousands of fatalities each year. What if there was a way to use stem-cell regeneration to prevent the devastating after-effects of a heart attack? According to researchers presenting a Japanese study at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting, this therapy exists and could potentially prevent dangerous cardiac tissue damage.

Novel PET imaging of the hallmark neurofibrillary tangles in Alzheimer’s disease using F-18 THK5117 has nabbed the Society of Nuclear Medicine and Molecular Imaging’s 2014 Image of the Year award. The study involved a head-to-head comparison of tau and amyloid PET imaging to verify whether tau PET can image the progression of Alzheimer’s pathology.

High-powered radioluminescence microscopy can home in on extremely scarce malignant cells among billions of normal cells in a blood sample. Leveraging the molecular imaging of circulating tumor cells (CTCs) could mean early detection of metastasis and the potential to improve survival for patients with several varieties of cancer, according to a study presented today during the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2014 Annual Meeting press conference.

ST. LOUIS--As the weekend opening of the 61st Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting sunsets, three more days full of meetings, presentations and exhibitions approach. See an SNMMI-hosted audiovisual montage of highlights and attendee interviews from the first two days of the conference.

Los Angeles-based biomedical firm ImaginAb has announced June 3 that the company is working with researchers at the University of California and has settled on a technology licensing agreement for the developmentof investigational immune cell PET agents.

ImaginAb, Inc., in collaboration with Memorial Sloan-Kettering Cancer Center (MKSCC), will be presenting initial clinical data with an anti-PSMA recombinant antibody fragment (a "minibody") derived from the huJ591 monoclonal antibody, in patients with metastatic prostate cancer. The presentation of this initial data coincides with the Company's preparation to expand the clinical development of this promising imaging agent in the US and internationally.

Remediation of Parkinson’s via stem cell transplantation has been verified and dopamine transporter (DAT) expression was found to be normal not just in short-term studies, but for 4-14 years after transplantation of dopamine neurons, according to a study published June 5 in Cell Reports.